Innovation to Meet the Needs of Evolving Cancer Hallmarks

Your aim may be to investigate cancer’s genetic origins, establish the mechanism of action or clinical implications of tumor biomarkers, or develop a targeted pharmaceutical or cellular therapy. At Enzo, our aim is to support yours. As cancer hallmarks have evolved over the last decade, so has our portfolio of tools to support cancer research. Over this time, we have called upon our diverse scientific and technical expertise to create innovative assays and reagents in the fields of epigenetics, autophagy, and Wnt research. These novel tools, and a broad portfolio of products established for decades in peer-reviewed literature, will help support cancer discovery into the next decade, and beyond. We are continually focused on enabling a future with more hope, more collaboration, more discovery, and less disease.

AMPIVIEW™ RNA Probes

AMPIVIEW™ RNA probes are uniquely designed with the precision of targeted, sequence-specific RNA probes, powered by Enzo’s LoopRNA ISH™ technology to deliver superior sensitivity. Additionally, sample morphology in tissue specimen is preserved and the signal of the targeted biomarker can be seen under the light microscope.

• High sensitivity and reliability with intense signal
• Optimized with cost-effective IHC/ISH detection solutions
• Flexible protocols for formalin-fixed, parafin-embedded (FFPE) tissues

CYTO-ID® Autophagy Detection Kit

A quantitative assay for monitoring autophagy in live cells

• No transfection required
• Proprietary dye stains autophagic vesicles with minimal lysosomal background
• Protocol validated with known inhibitors and activators of autophagic activity

GFP-CERTIFIED® Apoptosis/Necrosis Detection Kit

Multiplex assay to distinguish between healthy, early apoptotic, late apoptotic, and necrotic cell

• Specifically designed for use with GFP-expressing cell lines and cells expressing other fluorescent proteins (BFPs, CFPs)
• Optimized for both fluorescence microscopy and flow cytometry applications
• Suitable for use with live or post-fixed cells

CD Marker Specific Antibodies

We offer primary antibodies for studying exploratory biomarkers in cancer research. Whether your research is focused on apoptosis, autophagy, metabolism, metastasis, proliferation, and inflammation, we have a broad selection of antibodies to help ensure your success.

• Dependable, high quality antibodies for analyzing the hallmarks of cancer
• Validated for multiple applications
• Custom conjugation available

Solutions for aCGH Analysis

Array-based comparative genomic hybridization (aCGH) is a powerful platform for detecting DNA copy number gains and losses associated with chromosomal abnormalities in genetic diseases and cancers. The proprietary labeling technology and high-performance dyes incorporated into our aCGH kits enhance performance with commonly implemented microarray platforms.

CYTAG® SuperCGH Labeling Kit

• Validated for blood, amniotic fluid, postnatal, and oncology samples
• Label low input samples, providing excellent dynamic analytical range down to 50 ng
• Shorter workflow has samples ready for hybridization in < 4

Enzo Life Sciences offers the SCREEN-WELL® Cancer Library, a collection of 275 compounds that can be used for screening and assay development. The library contains small molecule inhibitors that affect mTOR, aurora kinases, tyrosine kinases, PI3K, and HDAC, as well as many other structurally and mechanically different compound classes. The SCREEN-WELL® Cancer Library is an essential tool for drug development and cancer inhibitor screening.

From Target Selection to Lead Profiling

Akt/PKB has emerged as a central player in the signal transduction pathways activated in response to growth factors or insulin. It is thought to contribute to several cellular functions including cell growth, transcriptional regulation, cell survival and nutrient metabolism. It has been linked to a range of diseases including cancer and type II diabetes.

The Akt/PKB pathway is a popular target since it sits at the crossroads of both oncogenic and tumor suppressor signaling pathways. Enzo provides novel tools to help support cancer discovery from target selection, hit-to-lead discovery, and lead profiling.

Novel Serine Protease Cancer Biomarker Products

Enzo Life Sciences offers more than 40 unique serine protease related products specifically related to cancer biomarker discovery, with emphasis on key family members identified as markers of early stage ovarian, breast, prostate and lung cancer.

• High-sensitivity, easy-to use and rapid ELISA kits
• Ready-to-user proteins for use as ELISA or Western blot standards
• Exclusive antibodies created against native proteins

• Modulate with high-purity small molecules & active proteins
• Label with proprietary DNA & RNA amplification & labeling technologies
• Detect with sensitive, widely-published biomarker ELISAs, antibodies & cell-based assays